Plasmid interleukin-23 (IL-23), but not plasmid IL-27, enhances the protective efficacy of a DNA vaccine against Mycobacterium tuberculosis infection.
about
T cell-mediated host immune defenses in the lungIdentification of potential cytokine pathways for therapeutic intervention in murine primary biliary cirrhosisTh17 cytokines and vaccine-induced immunity.Mycobacterium bovis BCG-specific Th17 cells confer partial protection against Mycobacterium tuberculosis infection in the absence of gamma interferonIntranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives.Increased pulmonary tumor necrosis factor alpha, interleukin-6 (IL-6), and IL-17A responses compensate for decreased gamma interferon production in anti-IL-12 autovaccine-treated, Mycobacterium bovis BCG-vaccinated mice.IL-17 and Th17 cells in tuberculosisInterleukin-12 and tuberculosis: an old story revisitedLactoferrin enhanced efficacy of the BCG vaccine to generate host protective responses against challenge with virulent Mycobacterium tuberculosisEffects of DNA- and Mycobacterium bovis BCG-based delivery of the Flt3 ligand on protective immunity to Mycobacterium tuberculosis.Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category.Life and death in the granuloma: immunopathology of tuberculosis.IL-10 dependent suppression of type 1, type 2 and type 17 cytokines in active pulmonary tuberculosisDNA vaccines against mycobacterial diseases.TLR9 regulates the mycobacteria-elicited pulmonary granulomatous immune response in mice through DC-derived Notch ligand delta-like 4IL-23 and IL-17 in tuberculosis.Regulatory T cells modulate Th17 responses in patients with positive tuberculin skin test results.Modulation of the Immune Response to DNA Vaccine Encoding Gene of 8-kDa Subunit of Echinococcus granulosus Antigen B Using Murine Interleukin-12 Plasmid in BALB/c MiceCytokine therapy of tuberculosis at the crossroads.Novel approaches to tuberculosis prevention: DNA vaccines.Cytokines and Chemokines in Mycobacterium tuberculosis Infection.Interluekin-17A (IL17A).Cytokine Polymorphisms, Their Influence and Levels in Brazilian Patients with Pulmonary Tuberculosis during Antituberculosis Treatment.Role of Interferons in the Development of Diagnostics, Vaccines, and Therapy for Tuberculosis.Administration of DNA Encoding the Interleukin-27 Gene Augments Antitumour Responses through Non-adaptive Immunity.Pattern recognition receptors and cytokines in Mycobacterium tuberculosis infection--the double-edged sword?Lack of Mycobacterium tuberculosis-specific interleukin-17A-producing CD4+ T cells in active disease.Formulation in DDA-MPLA-TDB Liposome Enhances the Immunogenicity and Protective Efficacy of a DNA Vaccine against Mycobacterium tuberculosis Infection.DNA vaccines against tuberculosisNew Aspects in Immunopathology of Mycobacterium tuberculosis
P2860
Q28395374-5FDB7D59-2EB2-4F85-8198-78C8B1C2DCF2Q28533202-A17A0DF1-5A20-4063-A075-C76E97167593Q33792227-8545D73B-E99D-498B-A31D-E00B11F9D3A1Q34177268-E94D441E-3A5C-4F59-8665-0659A5599C0FQ34309830-56DAD642-FB5E-41E9-A7DE-BC2FCD7C5A3FQ34484151-12D105F7-E461-4F22-BE72-D79EA85236C0Q34545889-C7176FD6-FE10-4656-9159-A627523331D5Q36137298-71E6B800-EE12-4997-9563-76BC3C844719Q36143523-190444BD-7836-406E-B2C6-A73BC587D05BQ36313882-393FB527-43D7-417A-8172-7BABF1E286A4Q36537915-E8F75C1D-C775-488C-9965-460B849D0EB2Q36703585-D23A532C-72A2-489D-A0EC-96AD0147317FQ36721480-0FA9D3A8-4196-4558-A704-0BED88245BFAQ36895737-B3B05ED2-38B9-4F1A-9E75-24D8D3EFDB1BQ37036047-0713E536-7562-4C8B-9A35-9B81D2F897E3Q37064619-7A311603-5411-4DDE-8FBD-E0607F8D3A0BQ37468253-C15711FD-F39D-4DC6-A26F-A64D63F83C44Q37597012-D96F6028-954A-4F99-990D-E91BD2ED4DE1Q37754962-AF336484-8037-4B61-8EAF-8AE5CB75A803Q38180804-B4ADF7C9-0635-4780-A7C9-064D798D7855Q38986062-CA850856-5BA9-4F30-8689-2E0342B1403BQ39103136-A1812B9E-6A38-4E24-97F5-B71A7F7AE69CQ39349883-E350EF3A-7F81-44BD-88F7-9C8BEE183C01Q39438318-4D913345-B930-4B01-B0D7-664E7AC65295Q40814716-C70A0BB1-7BAD-4EC4-A86A-3B2AB3B89294Q42236324-031D1911-DC84-45BB-A105-FC6AF900E7C5Q44318621-D030516A-CC8F-42A2-99B5-F496CAEB53EAQ52356828-D59D4BF0-23D3-4F1C-9E88-68D639EAC064Q57203104-6FCE0C5B-B4D8-44EC-ABCF-F054193F6425Q58905565-4221999C-2FC0-446D-A5D7-39AF6E3F1F25
P2860
Plasmid interleukin-23 (IL-23), but not plasmid IL-27, enhances the protective efficacy of a DNA vaccine against Mycobacterium tuberculosis infection.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Plasmid interleukin-23 (IL-23) ...... terium tuberculosis infection.
@ast
Plasmid interleukin-23 (IL-23) ...... terium tuberculosis infection.
@en
Plasmid interleukin-23 (IL-23) ...... terium tuberculosis infection.
@nl
type
label
Plasmid interleukin-23 (IL-23) ...... terium tuberculosis infection.
@ast
Plasmid interleukin-23 (IL-23) ...... terium tuberculosis infection.
@en
Plasmid interleukin-23 (IL-23) ...... terium tuberculosis infection.
@nl
prefLabel
Plasmid interleukin-23 (IL-23) ...... terium tuberculosis infection.
@ast
Plasmid interleukin-23 (IL-23) ...... terium tuberculosis infection.
@en
Plasmid interleukin-23 (IL-23) ...... terium tuberculosis infection.
@nl
P2093
P2860
P1476
Plasmid interleukin-23 (IL-23) ...... cterium tuberculosis infection
@en
P2093
Anthony A Ryan
James A Triccas
Warwick J Britton
P2860
P304
P356
10.1128/IAI.74.1.557-565.2006
P407
P577
2006-01-01T00:00:00Z